A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

NCT05912244 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: IO102/IO103
DRUG: Nivolumab-Relatlimab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

IO Biotech